Delivery Order SPE2DB20D1100-SPE2DB25FE4C7
Award Date 9/2/25
Potential Completion Date 9/3/25
Potential Value $9.3K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $15,525.98 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, reflecting the...
- The Defense Logistics Agency awarded a $1,906.45 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on August 18, 2025. This non-competitive delivery order represents a firm fixed price transaction with a performance completion date of August 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injectors on September 3, 2025, with completion expected by September 4, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The order will be...
- The Defense Logistics Agency awarded a $5,918.72 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on June 2, 2025, with an ultimate completion date of June 3, 2025. This competitive, non-set-aside award was issued from AmerisourceBergen's Conshohocken, Pennsylvania location and represents a single delivery order under the company's larger contract vehicle with DLA. Zepbound (tirzepatide) is a GLP-1 receptor agonist used for weight management...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The Defense Logistics Agency awarded a $12,414.97 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on July 31, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price contract represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management in patients with obesity or overweight conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $23,689.76 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on November 6, 2025, with an ultimate completion date of November 7, 2025. This competitive delivery order uses firm fixed pricing with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used for...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with a ceiling value of $2,669.03. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal vendor for military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $19,897.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors with a ceiling value of $3,812.90. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under...